JP2021523717A5 - - Google Patents
Info
- Publication number
- JP2021523717A5 JP2021523717A5 JP2020564104A JP2020564104A JP2021523717A5 JP 2021523717 A5 JP2021523717 A5 JP 2021523717A5 JP 2020564104 A JP2020564104 A JP 2020564104A JP 2020564104 A JP2020564104 A JP 2020564104A JP 2021523717 A5 JP2021523717 A5 JP 2021523717A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune cells
- population
- modified immune
- population according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670962P | 2018-05-14 | 2018-05-14 | |
| US62/670,962 | 2018-05-14 | ||
| PCT/US2019/031296 WO2019221991A1 (en) | 2018-05-14 | 2019-05-08 | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523717A JP2021523717A (ja) | 2021-09-09 |
| JP2021523717A5 true JP2021523717A5 (cg-RX-API-DMAC7.html) | 2022-05-17 |
Family
ID=68540927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564104A Pending JP2021523717A (ja) | 2018-05-14 | 2019-05-08 | 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12109236B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3793574A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021523717A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112888446A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019269318A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3100312A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019221991A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7793517B2 (ja) * | 2019-11-28 | 2026-01-05 | アムニオティクス・アーベー | ソース細胞から決定的造血細胞を生成する方法 |
| CN111733154B (zh) * | 2020-04-30 | 2022-11-04 | 和也健康科技有限公司 | 磁场处理的免疫细胞及其用途 |
| KR20230042671A (ko) * | 2020-05-28 | 2023-03-29 | 바이오마그네틱 솔루션스 엘엘씨 | 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법 |
| EP4419541A4 (en) * | 2021-10-21 | 2025-12-17 | Univ Texas | METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| US6448717B1 (en) | 2000-07-17 | 2002-09-10 | Micron Technology, Inc. | Method and apparatuses for providing uniform electron beams from field emission displays |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| EP3349770A1 (en) * | 2015-09-14 | 2018-07-25 | Regents of the University of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| US20180371052A1 (en) | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| EP3452580B1 (en) | 2016-05-02 | 2023-08-16 | Cerus Corporation | Compositions and methods for improved nk cell therapies |
-
2019
- 2019-05-08 CA CA3100312A patent/CA3100312A1/en active Pending
- 2019-05-08 AU AU2019269318A patent/AU2019269318A1/en not_active Abandoned
- 2019-05-08 US US17/055,525 patent/US12109236B2/en active Active
- 2019-05-08 JP JP2020564104A patent/JP2021523717A/ja active Pending
- 2019-05-08 EP EP19803724.4A patent/EP3793574A4/en not_active Withdrawn
- 2019-05-08 WO PCT/US2019/031296 patent/WO2019221991A1/en not_active Ceased
- 2019-05-08 CN CN201980046610.6A patent/CN112888446A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Galland et al. | Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression | |
| Gao et al. | Interleukin-10 genetically modified clinical-grade mesenchymal stromal cells markedly reinforced functional recovery after spinal cord injury via directing alternative activation of macrophages | |
| Bianchi et al. | Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells | |
| Martinez et al. | Overexpression of hypoxia-inducible factor 1 alpha improves immunomodulation by dental mesenchymal stem cells | |
| Zhu et al. | Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo | |
| JP6992809B2 (ja) | 免疫疾患の治療のための高効能幹細胞の選別方法 | |
| Marigo et al. | The immunomodulatory properties of mesenchymal stem cells | |
| Ozawa et al. | Cell and gene therapy using mesenchymal stem cells (MSCs) | |
| Janssens et al. | Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis | |
| Huang et al. | Cellular crosstalk in the bone marrow niche | |
| Papait et al. | The multifaceted roles of MSCs in the tumor microenvironment: interactions with immune cells and exploitation for therapy | |
| Song et al. | Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms | |
| Ye et al. | Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics | |
| Tang et al. | The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics | |
| Vladimirovna et al. | Mesenchymal stem cells and myeloid derived suppressor cells: common traits in immune regulation | |
| Yang et al. | Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation | |
| Cifù et al. | The exposure to osteoarthritic synovial fluid enhances the immunomodulatory profile of adipose mesenchymal stem cell secretome | |
| Ding et al. | The monocytes that repopulate in mice after cyclophosphamide treatment acquire a neutrophil precursor gene signature and immunosuppressive activity | |
| Andrlova et al. | An unconventional view of T cell reconstitution after allogeneic hematopoietic cell transplantation | |
| US20220381772A1 (en) | Systems and methods for evaluating nk cells | |
| JP2021512164A (ja) | トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞 | |
| JP2021523717A (ja) | 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 | |
| Hasegawa et al. | Effective-mononuclear cell (E-MNC) therapy alleviates salivary gland damage by suppressing lymphocyte infiltration in Sjögren-like disease | |
| Wang et al. | Update on cancer related issues of mesenchymal stem cell-based therapies | |
| Pyaram et al. | Advances in NKT cell immunotherapy for glioblastoma |